RUNX2

Across TCGA pan-cancer cohorts, RUNX2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RUNX2 data layer compared with 32 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher RUNX2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RUNX2 expression acts as an unfavorable survival marker, although some lineages such as GBM and HNSC show a favorable association.

GBM, LSCC, and HNSC are the cancer types where RUNX2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	DFS	Median	All	0.783	0.479	.023	13	view →
LSCC	DFS	Quartile	II,III,IV	0.690	1.000	.004	10	view →
HNSC	OS	Median	III,IV	1.000	0.344	.019	6	view →
CCRCC	OS	Quartile	All	0.403	1.000	.036	6	view →
PDAC	OS	Quartile	All	0.289	0.638	.014	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RUNX2–GBM (DFS)

Open the GBM breakdown →